Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 1956-1962

  Mittendorf, Elizabeth A ^a,b,c   Jeruss, Jacqueline S ^a,b,c   Tucker, Susan L ^a,b,c   Kolli, Aparna ^a,b,c   Newman, Lisa A ^a,b,c   Gonzalez Angulo, Ana M ^a,b,c   Buchholz, Thomas A ^a,b,c   Sahin, Aysegul A ^a,b,c   Cormier, Janice N ^a,b,c   Buzdar, Aman U ^a,b,c   Hortobagyi, Gabriel N ^a,b,c   Hunt, Kelly K ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EXTERNAL VALIDITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 79956290873     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.8469     Document Type: Article

References (18)

1. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999 (Pubitemid 29075229)
2. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998 (Pubitemid 28363030)
3. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998 (Pubitemid 28041584)
4. Carey LA, Metzger R, Dees EC, et al: American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97:1137-1142, 2005 (Pubitemid 41511213)
5. Jeruss JS, Mittendorf EA, Tucker SL, et al: Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26:246-252, 2008
6. Jeruss JS, Mittendorf EA, Tucker SL, et al: Staging of breast cancer in the neoadjuvant setting. Cancer Res 68:6477-6481, 2008
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Greenwood M: A Report of the Natural Duration of Cancer. London, United Kingdom, Her Majesty's Stationery Office, 1926
9. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997 (Pubitemid 27289876)
10. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005 (Pubitemid 40740554)
11. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
12. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003 (Pubitemid 46594124)
13. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007 (Pubitemid 350013847)
14. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
16. Mittendorf EA, Wu Y, Scaltriti M, et al: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15:7381-7388, 2009
17. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007 (Pubitemid 46121873)
18. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005